NEW YORK – Meridian Bioscience today reported a 6 percent year-over-year decrease in its fiscal third quarter revenues driven primarily by competitive pressures in the diagnostics segment.

The Cincinnati-based life science and diagnostics firm recorded revenues of $48.4 million compared to $51.7 million a year ago, missing analysts' consensus estimate of $49.8 million.